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Abstract
Current myocarditis guidelines do not advocate treatment to prevent myocardial injury and scar deposition in patients with 
myocarditis and normal left ventricular ejection fraction. We aimed to ascertain the utility of beta blockers, calcium channel 
blockers and antagonists of the renin–angiotensin system in ameliorating myocardial injury, scar formation and calcification 
in animal in vivo models of myocarditis. The project was prospectively registered with the PROSPERO database of systematic 
reviews (CRD42018089336). Primary outcomes (necrosis, fibrosis and calcification) were meta-analysed with random-effects 
modelling. 52 studies were systematically reviewed. Meta-analysis was performed compared with untreated controls. In each 
study, we identified all independent comparisons of treatment versus control groups. The pooled weighted mean difference 
(WMD) indicated treatment reduced necrosis by 16.9% (71 controlled analyses, 95% CI 13.2–20.7%; P < 0.001), however 
there was less evidence of an effect after accounting for publication bias. Treatment led to a 12.8% reduction in fibrosis (73 
controlled analyses, 95% CI 7.6–18.0%; P < 0.001). After accounting for publication bias this was attenuated to 7.8% but 
remained significant. Treatment reduced calcification by 4.1% (28 controlled analyses, 95% CI 0.2–8.0%; P < 0.0395). We 
observed significant heterogeneity in effect size in all primary endpoints, which was predominantly driven by differences 
between drug categories. Beta blockers and angiotensin-converting enzyme (ACE) inhibitors were the only agents that were 
effective for both necrosis and fibrosis, while only ACE inhibitors had a significant effect on calcification. This study provides 
evidence for a role for ACE inhibitors and beta blockers to prevent myocardial injury and scar deposition in in vivo models 
of myocarditis. There is a need for further well-designed studies to assess the translational application of these treatments.
Keywords Myocarditis · Remodelling · Drug treatment · Necrosis · Fibrosis · Calcification · Systematic review · Meta-
analysis
Introduction
Myocarditis is broadly defined as inflammation of the 
myocardium, diagnosed using histological and immuno-
histochemical criteria [1]. Although its aetiology and clini-
cal presentation are heterogenous, viral infections are the 
most important cause of myocarditis in North America and 
Europe, and dilated cardiomyopathy can ensue [2]. For 
example, biopsy-proven myocarditis has been reported in 
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9–16% of adult patients with unexplained dilated cardiomyo-
pathy, and is associated with poor prognosis [2–4].
Like the response to acute myocardial infarction, the 
pathogenesis of myocarditis relates to a robust inflammatory 
response. Initially, the noxious insult (typically infectious or 
autoimmune) initiates cellular necrosis. This stimulates the 
recruitment of circulating immune cells, which initiate the 
deposition of extracellular matrix and myocardial fibrosis. 
This, in turn, can result in left ventricular (LV) remodelling, 
progressive functional deterioration and, consequently, poor 
outcomes [3–5].
The presence of late gadolinium enhancement on car-
diovascular magnetic resonance (CMR) imaging correlates 
with replacement fibrosis on histology in dilated cardiomyo-
pathy [6, 7]. Late gadolinium enhancement in patients with 
myocarditis has also been associated with increased risk of 
major adverse cardiac events (MACE), even after correction 
for LV systolic function [8–10]. Myocardial fibrosis after 
myocarditis therefore appears to be an important therapeutic 
target in humans.
Animal in vivo myocarditis is typically induced by virus 
inoculation or immunization with cardiac myosin. Several 
pre-clinical studies have reported a beneficial effect of drug 
treatment on necrosis and fibrosis, including with beta block-
ers, calcium channel blockers (CCB) and antagonists of the 
renin–angiotensin system [RAS, including angiotensin-
converting-enzyme (ACE) inhibitors, angiotensin recep-
tor blockers (ARB), direct renin inhibitors and aldosterone 
antagonists (MRA)]. Furthermore, myocardial calcification 
is a common consequence of in vivo myocarditis, albeit 
infrequent in humans, which is commonly prevented by drug 
treatment in these studies.
Despite this evidence, there is a paucity of clinical tri-
als and it is not known if treatment with these drug classes 
can prevent myocardial injury and scar formation in patients 
with myocarditis in the presence of normal LV ejection frac-
tion. Consequently, current treatment recommendations in 
humans focus on supportive therapies, immunomodulation 
and immunosuppression [2, 11]. We performed a system-
atic review and meta-analysis to delineate the association 
between beta blockers, calcium channel blockers and RAS 
antagonists and necrosis, fibrosis and calcification in in vivo 
myocarditis. Furthermore, we aimed to examine determi-
nants of efficacy of drug treatment in pre-clinical experi-
ments to facilitate translation to clinical trials.
Methods
The project was prospectively registered with the PROS-
PERO database of systematic reviews (CRD42018089336) 
and performed in accordance with Preferred Reporting 
Items for Systematic reviews and Meta-Analyses (PRISMA) 
guidelines [12].
Search strategy and eligibility criteria
A systematic review of Medline (1946–26th February 2019) 
and Embase (1974–26th February 2019) was performed. Lit-
erature searches were conducted independently by JS and 
DB. The search strategy included keywords and MeSH terms 
relating to experimental myocarditis and treatment with beta 
blockers, calcium channel blockers and RAS antagonists 
(Supplementary material). This was developed by DB and 
JS using published guidelines [13–15], and peer reviewed 
by members of the King’s College London NHS Trust Heart 
Failure Unit. Our search was limited to reports available 
in English due to limited time and financial resources for 
translation. Review articles, abstract articles, unpublished 
material and ongoing studies were excluded. Duplicates 
were removed using Endnote (Thomas Reuters, US) and all 
remaining results subjected to eligibility screening.
Study eligibility criteria were defined using the PICOS 
approach [16]. In vivo animal studies were included if they 
investigated the effect of any of beta blockers, CCB and 
RAS antagonists (including ACE inhibitors, ARB, MRA 
and direct renin inhibitors) vs. control (sham treatment) on 
histological parameters of myocardial injury and scar for-
mation, including necrosis, calcification or fibrosis, in any 
mammalian species with experimental myocarditis, regard-
less of study design.
Studies were excluded if they did not report a histological 
endpoint relating to scar formation (necrosis, calcification 
and fibrosis) [17–30]. Furthermore, only those using stand-
ard scoring criteria (see Araki et al. [31]) were included. 
Myocarditis induced by Chagas (Trypanosoma cruzi) was 
excluded, so were animals with co-morbidities or co-inter-
vention other than the induction of myocarditis. Groups were 
excluded where an eligible medication was administered in 
combination with another medication (including other eligi-
ble medications) or procedure likely to affect the outcome. 
Finally, studies investigating neonatal animals (according to 
the study report) were excluded.
Data collection, synthesis and study quality
Retrieved records were screened for eligibility using the title 
and abstract, followed by the full text (Fig. 1). Eligibility 
assessment was performed in an un-blinded, standardized 
manner (using predefined data fields) by JS and DB inde-
pendently. All disagreements were resolved by examining 
the full text of the article and consensus between reviewers.
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Variables for which data were sought were those that 
were considered likely to affect the efficacy of experi-
mental myocarditis treatment. Data was independently 
extracted by two authors (JS and LD) using predefined 
data fields. We attempted to acquire missing information 
by contacting report authors [32–36]. Only experiments 
that were designed with homogeneity in population, inter-
vention, control and outcome were considered for pooling 
[16]. All data items and assumptions are listed in Supple-
mentary material.
Study level quality was assessed using SYRCLE’s risk 
of bias tool and an adapted CAMARADES checklist, 
both of which address key bias related to selection, per-
formance, detection, attrition and reporting [37, 38]. Study 
quality was assessed independently from data extraction 
and between assessors in an un-blinded, standardized man-
ner by OZ and AD. All disagreements were resolved by 
consensus. We examined available study protocols, study 
methods and results sections for selective reporting.
Primary and secondary outcomes
The predefined primary outcomes were the following 
parameters of scar formation: necrosis, fibrosis and cal-
cification. Secondary outcomes included survival, heart 
weight as a proportion of body weight (surrogate for LV 
mass), and inflammation.
Statistical methods
Measuring treatment effect
Continuous outcome data was analysed as percentage of 
myocardium involved, enabling use of weighted mean dif-
ference (WMD, i.e., control group mean minus experimen-
tal group mean) between intervention and control groups, 
rather than standardised mean difference. In each study, we 
identified all independent comparisons of treatment versus 
control groups. To avoid statistical over-estimation, where 
multiple comparisons were made to the same control group, 
the size of the control group was corrected for the number 
of comparisons made (n/number of comparisons) [16, 39]. 
For studies describing more than one outcome, each out-
come was analysed independently, and only one assessment 
of outcome was included per comparison.
Data synthesis
To account for anticipated heterogeneity, we pooled effect 
sizes using random-effects meta-analysis, which considers 
within-study and between-study variability and weights each 
study accordingly. Pooled effect size data for intervention 
and control groups were compared using the WMD and the 
corresponding standard deviation (SD), using the method 
of DerSimonian and Laird [40]. For the binary outcome of 
survival, pooled event data were compared using a relative 
risk (RR) with associated 95% confidence interval (CI).
Subgroup analysis, identification and explanation 
of heterogeneity
Heterogeneity was quantified using the Chi squared test, T2 
and I2 statistics, and was considered significant if I2 > 75% 
[39, 41]. To look for sources of heterogeneity, outcomes 
were assessed according to predefined experimental factors 
and quality indicators. Subgroup analyses defined a priori 
were according to drug class, species, sex, method of myo-
carditis induction, and histology method.
Meta‑regression and explanation of variability
Meta-regression was performed to assess the impact of the 
variables: timing of therapy, length of treatment and study 
quality, on the WMD. Primary meta-regression assess-
ment used residual maximum likelihood with random-
effects weighting and Knapp and Hartung t-distribution. 
Publication bias was assessed using Begg’s test and Egger’s 
test to identify small-study effects according to each of the 
Records screened after 
duplicates removed 
(n = 223)
Records excluded by 
abstract and title
(n = 132)
Full-text articles 
assessed for eligibility 
(n = 91) 
Full-text articles
excluded (n = 39) 
Not met inclusion criteria n = 29
Not intervention vs. control n = 8
Repeated data n = 1
Missing data n = 1
Meta-analyses included 
in quantitative synthesis 
(n = 52) 
in Medline search 
(n = 145) 
in EMBASE search
(n =  202) 
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Fig. 1  Flow chart of the study selection process. A systematic review 
yielded 347 reports. After removal of duplicates and the application 
of inclusion and exclusion criteria, 52 studies were included in the 
meta-analysis
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outcomes assessed. If publication bias was indicated, we 
further evaluated the number of missing studies in a meta-
analysis by the application of the trim-and-fill method and 
recalculated the pooled effect estimate with the addition of 
those missing studies [42]. A two-tailed P value of 0.01 was 
considered statistically significant. All analyses were per-
formed with STATA (version 13.1) and R (version 3.5.1).
Results
Study selection
The search strategy identified 52 studies for systematic 
review (Fig. 1, Table 1). Overall, 24, 34 and 9 studies inves-
tigated necrosis, fibrosis and calcification, respectively. For 
secondary outcomes this was 31, 38 and 24 investigating 
survival, heart weight:body weight ratio(HW/BW) and 
inflammation, respectively.
Study characteristics
The main characteristics of included studies, and their ref-
erences, are given in Supplementary material. All studies 
used hematoxylin and eosin (HE) staining for inflamma-
tion, calcification and necrosis, except for the study by Liu 
et al. that used Masson’s trichrome to measure necrosis [43]. 
Studies used one of three stains for fibrosis: Masson’s tri-
chrome, Azan-Mallory or HE. Experimental animals were 
predominantly male, although studies of calcification used 
a mix of sexes. Studies typically induced myocarditis with a 
virus, except for survival and HW/BW (used a mix of viral 
and autoimmune induction) and fibrosis (more commonly 
autoimmune). Studies used either a mix of mice and rats 
(fibrosis, survival, HW/BW) or predominantly mice (necro-
sis, calcification, inflammation). With respect to drug class, 
most outcomes were assessed using a good range of drug 
classes. Notable exceptions are fibrosis, which included a 
small number of studies using CCB, MRA and direct renin 
inhibitors, and calcification, which was only tested with 
ACE inhibitors, ARB and beta blockers. Furthermore, 
MRA treatment was only used in a small number of studies 
investigating survival, fibrosis and HW/BW and, overall, few 
studies used direct renin inhibitor and CCB treatment. All 
analyses included a mix of manual and automatic measure-
ment, except for necrosis, calcification and inflammation, 
which were mostly manual.
Study quality and risk of bias
Reports achieved a median SYRCLE risk of bias tool score 
of 5 (interquartile range 4–7; Fig. 2) out of 10 and a median 
adapted CAMARADES checklist score of 5 (interquartile 
range 4–5; Fig. 2). For example, using the SYRCLE risk of 
bias tool, only 9% reported random outcome assessment, 
43% reported allocation concealment and 43% reported 
blinding to experimental protocol. Similarly, using the 
adapted CAMARADES checklist, no studies reported exper-
imental temperature control or sample size calculation, and 
only 9% reported blinded application of treatment. A full 
breakdown of scores is included in the Supplementary mate-
rial. Meta-regression indicated that neither the SYRCLE nor 
CAMARADES study quality score was associated with any 
of the endpoints tested (see Supplementary material).
Meta‑analysis of treatment efficacy
All studies had extractable data and contributed to meta-
analysis, which was performed for six outcomes: necrosis, 
fibrosis, calcification, inflammation, survival, HW/BW. A 
summary of the individual meta-analyses performed is pre-
sented in Figs. 3, 4 and detailed results are discussed below.
Necrosis
Data on 71 comparisons of drug intervention versus control 
was extracted. Overall, the included study drugs reduced 
necrosis by 16.9% (95% CI 13.2–20.7%) when compared 
to untreated controls (P < 0.001; Supplementary Fig. S1). 
Subgroup analysis according to drug class revealed a similar 
effect for all included classes with the exception of CCB, 
which was associated with a neutral effect on necrosis (0.9%; 
Table 1  Summary of studies 
grouped according to outcome Outcomes Studies (n) Analyses (n) Treated animals Control animals
Primary
 Necrosis 24 71 682 450
 Fibrosis 34 73 842 502
 Calcification 9 28 334 238
Secondary
 Survival 31 99 1918 1161
 HW/BW 38 95 975 582
 Inflammation 24 69 706 495
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95% CI − 8.0 to 9.8%; P = 0.80; n = 6; Fig. 3). Significant 
heterogeneity was observed in the overall analysis (T2 124.2 
and I2 91.1%; P < 0.001). Subgroup analyses demonstrated 
that the main selected covariates contributing to this het-
erogeneity were drug class (residual I2 86%; P < 0.01), sex 
(the mixed sex group had a lower pooled WMD than the 
male and female sex groups, residual I2 89%; P < 0.01) and 
measurement method (the automatic measurement group 
had a lower pooled WMD than the manual and ‘not stated’ 
groups, residual I2 90%; P < 0.01). Meta-regression did not 
show any impact of timing of therapy, length of treatment 
or study quality on WMD (Supplementary Tables S11–12).
Fibrosis
Data on 73 controlled comparisons was extracted. Overall, 
the included study drugs reduced fibrosis by 12.8% (95% 
CI 7.6–18.0%; P < 0.001), when compared to untreated 
Fig. 2  Reporting of study 
quality indicators. Study 
quality was assessed using the 
CAMRADES checklist (a) and 
SYRCLE risk of bias tool (b). 
Values are expressed as the 
percentage of studies reporting 
each quality indicator
Peer reviewed journal
Randomisation
Blinded assessment of outcomes
Comorbid animals
Regulatory compliance statement
Confirmation method of myocarditis
Statement of control of temp
Sample size calculation
Blinded application of treatment
Statement of conflict of interest
0% 25% 50% 75% 100%
Passed study quality criteria? Yes No
CAMARADES Guidelines
Sequence generation
Baseline characteristics
Allocation concealment
Random housing
Blinding of investigators
Random outcome assessment
Blinding of assessors
Incomplete outcome data
Selective outcome reporting
Other sources of bias
0% 25% 50% 75% 100%
Risk of bias Low High
SYRCLE risk of bias toolB
A
 Basic Research in Cardiology (2019) 114:48
1 3
48 Page 6 of 14
controls (P < 0.001; Supplementary Fig. S2). With respect 
to drug class, a similar effect was observed for all included 
classes with the exception of ARBs (7.7%; 95% CI − 20.7 
to 36.1%; P = 0.57; n = 19) and MRAs (14.5%; 95% CI 
−3.7 to 32.7%; P = 0.08; n = 3; Fig. 3). Significant hetero-
geneity was observed in the overall analysis (T2 98.0 and 
I2 90.4%; P < 0.001). The main selected covariates contrib-
uting to heterogeneity were drug class (residual I2 89%; 
P < 0.01), species (rats had a higher pooled WMD than 
mice, residual I2 88%; P < 0.01) and myocarditis induc-
tion method (the cardiac myosin and clozapine groups had 
higher pooled WMD, residual I2 87%, P < 0.01). In addi-
tion, post hoc analysis of staining method showed that 
studies using Masson’s trichrome did not reach signifi-
cance (residual I2 88%, P < 0.01; Supplementary Fig. S3). 
Meta-regression did not show any impact of timing of 
therapy, length of treatment or study quality on WMD 
(Supplementary Tables S13–14).
Fig. 3  Summary plot of meta-
analysis of drug efficacy for pri-
mary outcomes. Forest plots of 
the effect of eligible treatments 
on primary outcomes, pooled 
using random-effects meta-
analysis. Overall, 172 controlled 
comparisons were included. The 
diamonds represent the pooled 
difference using a random-
effects model. I2 is the percent-
age of total variation across 
studies due to heterogeneity. 
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Calcification
Data on 28 controlled comparisons was extracted. Over-
all, the included study drugs reduced calcification by 4.1% 
(95% CI 0.2–8.0%) when compared to untreated controls 
(P < 0.001; Supplementary Fig. S4). With respect to drug 
class, only ACE inhibitors achieved significance (7.4%; 
95% CI 1.1–13.6%; P = 0.02; n = 13; Fig. 3). In the overall 
Fig. 4  Summary plot of meta-
analysis of drug efficacy for 
secondary outcomes. Forest 
plots of the effect of eligible 
treatments on secondary out-
comes, pooled using random-
effects meta-analysis. Overall, 
263 controlled comparisons 
were included. The diamonds 
represent the pooled difference 
using a random-effects model. 
I2 is the percentage of total 
variation across studies due to 
heterogeneity. CI Confidence 
interval, WMD weighted mean 
difference, RR relative risk
Summary of drug efficacy for secondary outcomes
WMD 95% CIOutcome
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analysis, there was no significant heterogeneity (T2 = 26.0 
and I2 = 50.1%; P = 0.001) and meta-regression did not show 
any impact of timing of therapy, length of treatment or study 
quality on WMD (Supplementary Tables S15–16).
Secondary outcomes
After initial data extraction, it was apparent that most stud-
ies included the additional outcome measures survival, 
HW/BW and inflammation. Although these are not directly 
related to myocardial injury and scar deposition they are 
of considerable interest and we therefore amended our pro-
tocol to include them as secondary endpoints. There were 
99, 95 and 69 controlled comparisons for meta-analysis of 
survival, HW/BW and inflammation, respectively. Overall, 
treatment improved survival (RR 0.69, 95% CI 0.62–0.76; 
P < 0.001), HW/BW (WMD 0.8; 95% CI 0.7–0.9; P < 0.001) 
and inflammation (WMD 15.4%; 95% CI 11.6–19.3%; 
P < 0.001), compared to untreated controls (Supplementary 
Figs. S5–7). With respect to drug class, the beneficial effect 
on survival was not seen with CCBs [RR 0.62 (0.36–1.07); 
P = 0.08; Fig. 4, Supplementary Table S17] or MRAs (RR 
0.83 (0.54–1.27); P = 0.26; Supplementary Table S17), and 
the improvement in inflammation was not seen with CCBs 
(WMD − 0.68%, 95% CI − 21.0 to 19.7%; P = 0.93; Supple-
mentary Table S21). Significant heterogeneity was observed 
in the overall analysis only for inflammmation (T2 = 149.2 
and I2 = 87.9%; P < 0.001) and the main tested covariate con-
tributing to this was sex (the mixed sex group had a lower 
pooled WMD than the male and female sex groups, residual 
I2 88%, P < 0.01). Meta-regression of the effect of timing of 
starting treatment confirmed that studies where treatment 
was started earlier had a greater association between drug 
intervention and improvement in inflammation (β = 0.78, 
P = 0.023). Detailed results are given in Supplementary 
Tables S17–22).
Publication bias
There was evidence of small study effects and publication 
bias for the necrosis outcome (P < 0.001; Supplementary 
Fig. S8). The application of the trim and fill method to 
recalculate the pooled effect estimate attenuated the WMD 
to 4.5% (95% CI − 0.3 to 9.2%), with less evidence of an 
effect (P = 0.06), indicating that the results were affected by 
publication bias. The fibrosis outcome showed similar evi-
dence for small study effects and publication bias (P = 0.039; 
Supplementary Fig. S9); however, the trim and fill method 
imputed a WMD of 7.8% (95% CI 2.6–13.0%) and although 
this attenuated the treatment effect, it remained significant 
(P = 0.004).
There was no evidence of small study effects or publi-
cation bias in the calcification or inflammation outcomes 
(Supplementary Figs. S10–11), while evidence for HW/
BW and survival was mixed (Supplementary Figs. S12–13) 
For HW/BW, trim and fill resulted in WMD of 0.6 (95% CI 
0.5–0.8; P < 0.0001), and for survival trim and fill resulted 
in a relative risk of 0.7 (95% CI 0.6–0.8; P < 0.0001), which 
both remain significant.
Discussion
We aimed to describe the effect of drug treatment on impor-
tant parameters of myocardial injury and scar formation in 
in vivo animal models of myocarditis using a systematic 
review and meta-analysis. We found a reduction in necro-
sis, fibrosis and calcification with therapy, compared to 
untreated control animals with myocarditis, based on data 
from 52 studies and 2220 animals. There were similar ben-
eficial effects on the secondary outcomes of survival, HW/
BW and inflammation. However, the significant impact on 
necrosis was less evident after correction for publication 
bias. Nonetheless, these are important observations in the 
context of the paucity of recommendations for prevention 
of myocardial injury and scar deposition after myocarditis 
in patients with normal LV systolic function in international 
guidelines [2].
Study characteristics
Experimental animals were predominantly male and most 
induced myocarditis by injection of the cardiotropic viruses 
Coxsackievirus B3 (CVB3) or encephalomyocarditis virus 
(EMCV), which directly mediate focal necrosis and is 
appropriate given that viral infections are the most impor-
tant cause of myocarditis in North America and Europe [2, 
44, 45].
Most outcomes were assessed using a good range of drug 
classes. Exceptions are that MRA treatment was only used 
in a small number of studies investigating survival, fibrosis 
and HW/BW. This is surprising as MRA therapy has the best 
evidence for treating fibrosis in the general heart failure liter-
ature [46]. Aldosterone stimulates fibrosis via Nox2-contain-
ing nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase [47], and MRAs have been shown to abrogate this 
effect in several pre-clinical studies and prospective rand-
omized trials in heart failure [48–53]. Similarly, few studies 
used direct renin inhibitor or CCB treatment.
With respect to histological stain, most studies used HE. 
While inflammation was not defined a priori, all studies used 
HE stains for this outcome and quantified mononuclear and 
polynuclear cellular infiltration. For fibrosis, studies used 
a mix of stains. Masson’s trichrome and Azan-Mallory are 
predominantly used for differentiating muscle and collagen, 
are typically used in studies of fibrosis, while HE is less 
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specific. However, post hoc analysis of staining method 
showed a similar overall trend regardless of stain. Although 
this did not reach significance for Masson’s trichrome, this 
is likely to relate to the small group size.
Study quality and risk of bias
Studies had mixed methodological quality that, together 
with publication bias, can lead to over-estimation of effect 
size [54–56], although no statistical association was evident 
using meta-regression. Confirmation of myocarditis was 
generally well reported which is reassuring. In addition, 
there was only infrequent selective outcome reporting and 
incomplete outcome data. However, there was only mixed 
observation of CAMARADES and SYRCLE guidelines 
and the worst-performing criteria typically related to study 
design, including sample size calculation, sequence genera-
tion, blinding and random allocation. In some cases, this will 
reflect unsatisfactory reporting (despite the criteria being 
met) but it appears more likely that studies are excessively 
biased due to omission of crucial elements of study design. 
These elements are particularly important as it is known that 
failure to do them can significantly increase effect size [57].
Treatment efficacy and sources of heterogeneity
There were high levels of heterogeneity between studies 
investigating necrosis, fibrosis, and inflammation, which 
should therefore be interpreted with caution. To explore fac-
tors that could account for heterogeneity, and to elucidate 
any determinants of drug efficacy, we performed subgroup 
analysis of a priori variables that we hypothesised were 
likely to impact on the efficacy of experimental myocarditis 
drug treatment. The approach of identifying variables that 
can influence an intervention’s efficacy may inform clinical 
study design and improve attempts to translate novel thera-
pies. For example, a meta-analysis of determinants of effi-
cacy of cardiac ischaemic preconditioning in animal studies 
suggested attenuated efficacy in comorbid animals, which 
may have important implications for clinical study design 
[58]. In the present study, the beneficial effects of drug treat-
ment were generally present across all subgroups and out-
comes. The important exception to this was drug class. This 
is likely to relate to a range of variability in efficacy within 
drug classes, depending on the specific agent used and its 
possible off-target effects, as well as some important differ-
ences between classes.
Drug class
The largest effect on necrosis was seen with ARB treatment 
and, although the mechanism for this is not clear, it has been 
attributed to attenuation of virus-mediated oxidative stress 
[59]. Treatment with beta blockers and ACE inhibitors was 
also effective in this context.
MRA treatment was only used in two studies investigat-
ing fibrosis in the present analysis and, where it was, it had 
no significant effect on fibrosis. In addition to the paucity of 
studies investigating CCB and direct renin inhibitor treat-
ment effects on fibrosis, this may account for heterogeneity 
related to drug class. Most of the available literature has 
investigated MRA therapy in heart failure secondary to 
ischaemic heart disease and it may be that there are system-
atic differences between this and myocarditis-induced fibro-
sis, although this has not been specifically investigated. ARB 
treatment was similarly neutral. In contrast, beta blockers 
and ACE inhibitors were beneficial, while the greatest effect 
was seen with CCB treatment. This may relate to direct 
inhibition of fibroblast activation by dihydropyridine cal-
cium channel blockers, possibly by inhibition of transform-
ing growth factor-β [60, 61], tumour necrosis factor-α or 
inducible nitric oxide synthase [62]. However, it should be 
noted that a clinical trial of a dihydropyridine CCB (amlodi-
pine) in chronic heart failure was neutral [63]. Furthermore, 
non-dihydropyridine CCBs to prevent ventricular remodel-
ling after acute myocardial infarction in the context of LV 
impairment have been associated with harm [64], despite 
similarly promising pre-clinical evidence [65].
Finally, drug class also contributed to significant hetero-
geneity in the inflammation outcome. Here, ACE, ARB, beta 
blocker and direct renin inhibitor treatment was effective 
in reducing inflammation in in vivo models of myocarditis. 
CCB treatment was ineffective at attenuating inflammation 
but was only tested in a small number of studies and this 
should be interpreted with caution. Interestingly, the major-
ity of evidence for immunosuppression relates to virus-neg-
ative myocarditis and this is reflected in trials registered on 
ClinicalTrials.gov and clinical guidelines [2]. This is sup-
ported by neutral results in trials recruiting patients with 
unknown aetiology [66]. In contrast, the majority of stud-
ies in our meta-analysis investigated inflammation in virus-
induced myocarditis models and found a reduction in the 
primary outcome measures despite significant anti-inflam-
matory effects. Furthermore, several studies measured virus 
replication and found no difference versus control despite 
evidence of reduced inflammation [67–70]. Taken together 
this suggests that, whatever the aetiology of myocarditis, 
treatment to prevent myocardial injury and fibrosis may be 
beneficial.
Overall, it appears ACE inhibitor and beta blocker treat-
ment might have the broadest effectiveness in preventing the 
most clinically relevant outcomes of necrosis and fibrosis 
in experimental myocarditis. ACE inhibition also prevented 
myocardial calcification. This is a rare clinical manifesta-
tion of myocarditis, largely confined to case reports, that 
has been associated with poor outcomes [71]. The positive 
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findings for ACE inhibitors and beta blockers complement 
the established literature for these drugs in chronic heart 
failure, most of which comes from their use after myocar-
dial infarction. However, no clinical trials have specifically 
investigated their use in the context of myocarditis in the 
absence of LV systolic dysfunction and only trials investi-
gating specific immunosuppressive therapies are registered 
on ClinicalTrials.gov. The only exception is the MIRACLE 
HIV study, which is studying the efficacy of eplerenone in 
patients with HIV on myocardial inflammation and fibrosis, 
but this is not a study of patients with myocarditis per se 
[72].
Animal sex
The second variable that influenced some outcomes was 
animal sex. Specifically, drug treatment had no significant 
impact on necrosis and inflammation in experiments using 
mixed sex experimental groups [33–35, 73]. However, no 
difference in drug efficacy was seen between male and 
female groups, and this finding should be interpreted with 
caution in view of the small number of comparisons, from 
only two research groups, available for subgroup analysis.
Timing of treatment
Finally, we found that improvement in inflammation, and a 
trend for fibrosis, were associated with the timing of start-
ing treatment. This suggests that the earlier treatment was 
started, the larger the effect. Although the drug classes we 
analysed are not anti-inflammatory per se, the anti-inflam-
matory effect we reported in this analysis has, for example, 
been attributed to reduced EMCV-induced inflammation by 
impeding interleukin-1 production in monocytes [74], and 
regulation of inflammatory cytokine expression from T cells 
[75]. Given that the inflammatory response to injury peaks 
in the first 3 days after injury, it follows that early treatment 
is likely to have the biggest effect.
Publication bias
There was evidence of small study effects and publication 
bias in several outcomes, which may affect the translational 
application of these findings. With respect to necrosis, while 
visual analysis of the funnel plot is reassuring, the appli-
cation of the trim and fill method abrogated a significant 
change in the WMD with drug therapy. Funnel plot asym-
metry was most marked in the fibrosis data, indicating the 
absence of small studies showing an improvement with drug 
treatment, suggesting that not all the relevant studies have 
been reported or included in the meta-analysis. However, 
after application of the trim and fill method, the treatment 
effect remains significant and may be expected to be more 
so should small positive studies be included. With respect to 
survival, visual assessment of the funnel plot suggests that 
small, negative studies may be under-represented. However, 
after application of the trim and fill method the treatment 
effect remains significant. In addition to true publication 
bias, funnel plot asymmetry can also result from study het-
erogeneity, which is a relevant consideration in the present 
meta-analysis [76].
Strengths and limitations
To our knowledge, this is the first systematic review and 
meta-analysis investigating non-immunotherapy treatment 
strategies in myocarditis using in vivo animal models. We 
included many studies and animals in intervention and con-
trol arms, which allowed for robust analysis of subgroups. 
Our review is based on reported results of independent pub-
lished studies, prepared according to explicit reproducible 
methods.
With respect to limitations, first, there was significant 
heterogeneity between studies in several analyses. We have 
accounted for this, at least in part, by using random-effects, 
subgroup analyses and meta-regression. However, there 
is residual heterogeneity that is likely to relate to other, 
unmeasured, variables as well as reflecting the inclusion 
of small, non-randomized studies and a degree of caution 
is necessary when interpreting the findings [77]. Second, 
no studies documented LV function at start of the experi-
ment. All studies used healthy mice and we excluded stud-
ies that included co-morbid animals, so it is reasonable to 
assume that baseline LV function was normal. In fact, very 
few studies examined cardiac morphology and function at 
all, although those that did typically reported worsening LV 
systolic function after myocarditis induction and at least par-
tial recovery with the experimental drug [61, 62, 78–82]. 
Third, as with all meta-analyses, the quality of reporting 
of the included studies is crucial to its validity, therefore 
studies with missing data were excluded. However, several 
studies did not meet important quality indices, especially 
with respect to including sample size calculation, sequence 
generation, blinding and random allocation and, although 
study quality was not related to any outcomes, it has been 
asserted that poorly performed animal studies should be 
interpreted with caution, especially when used as a rationale 
for human trials. Fourth, the included literature was dated, 
which reflects trends in cardiovascular research whereby 
more contemporary studies have investigated immunother-
apy for virus-negative myocarditis. Fifth, only English lan-
guage publications were considered. Sixth, it is important to 
acknowledge the possible impact of co-morbidities and other 
medications on the efficacy of drug treatment in myocardi-
tis. Pre-clinical animal models used frequently over-simplify 
complex co-morbidity, risk factor and medication profiles of 
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humans with myocarditis [83]. Studies using animals with 
co-morbidities were specifically excluded due to the limited 
number of available studies. Nonetheless, co-morbidities 
are an important consideration with respect to translational 
application of the present findings. Finally, we did not for-
mally assess the relative efficacy of these medications with 
respect to each other, using network meta-analysis, and this 
would be an interesting avenue for further exploration.
Clinical implications and conclusions
This systematic review and meta-analysis of in vivo, exper-
imental studies of myocarditis demonstrates a significant 
impact of treatment with beta blockers, calcium channel 
blockers or RAS antagonists in ameliorating necrosis, fibro-
sis and calcification. Observed heterogeneity was contingent 
on drug class. Beta blockers and ACE inhibitors were the 
only agents that were effective for both the clinically com-
mon sequalae of necrosis and fibrosis. They also attenuated 
inflammation together with improving HW/BW and sur-
vival. ACE inhibitors were also effective at preventing cal-
cification, although this is an unusual clinical manifestation.
Clinically, the use of CMR has allowed quantification 
of replacement fibrosis using late gadolinium enhance-
ment. This is a nidus for arrhythmia [84], and is associated 
with increased risk of MACE, even after adjustment for LV 
function [8–10]. This association remains in patients with 
LV ejection fraction ≥ 40%, a range in which prognostic 
heart failure medication is not indicated [8, 9]. In contrast, 
the absence of late gadolinium enhancement and normal 
LV ejection fraction was associated with a very low event 
rate [8, 9]. There is therefore an unmet need for therapeu-
tic agents that target myocyte necrosis and fibrosis in the 
context of myocarditis with normal LV ejection fraction at 
presentation.
To date, this meta-analysis provides the most robust pre-
clinical evidence for a role for ACE inhibitors or beta block-
ers in this setting. However, this enthusiasm is tempered 
by mixed methodological quality, risk of bias and the age 
of the literature. There is an urgent need for contemporary, 
well-performed studies using more advanced techniques and 
improved current understanding of the immune response to 
cardiac injury. In addition, more mechanistic studies are 
needed so we can better target therapy to patients who are 
most likely to gain benefit.
We advocate clinical studies investigating beta blockers 
and ACE inhibitors in patients presenting with myocardi-
tis in the absence of LV dysfunction. Such trials should 
cautiously consider investigating all aetiologies due to the 
apparent absence of harm in virus-induced myocarditis and 
starting treatment as early as practicable due to evidence of 
greater benefit.
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